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Abstract
Background: Numerous instruments have been developed to assess patient reported outcomes; most approaches
however focus on a single condition. With the increasing prevalence of multimorbidity, this might no longer be
appropriate. Moreover, a more comprehensive approach that facilitates shared decision making and stimulates self-
management is most likely more valuable for clinical practice than a questionnaire alone. This study aims to
transform the Assessment of Burden of Chronic Obstructive Pulmonary Disease (COPD) (ABC)-tool into the
Assessment of Burden of Chronic Conditions (ABCC)-tool for COPD, asthma, and diabetes mellitus type 2 (DM2).
The tool consists of a scale, a visualisation of the outcomes, and treatment advice.
Methods: Requirements for the tool were formulated. Questionnaires were developed based on a literature study
of existing questionnaires, clinical guidelines, interviews with patients and healthcare providers, and input from an
expert group. Cut-off points and treatment advice were determined to display the results and to provide practical
recommendations.
Results: The ABCC-scale consists of a generic questionnaire and disease-specific questionnaires, which can be
combined into a single individualized questionnaire for each patient. Results are displayed in one balloon chart, and
each domain includes practical recommendations.
Conclusions: The ABCC-tool is expected to facilitate conversations between a patient and a healthcare provider,
and to help formulate treatment plans and care plans with personalised goals. By facilitating an integrated
approach, this instrument can be applied in a variety of circumstances and disease combinations.
Keywords: Burden of disease, Chronic disease, ABCC-tool, Self-management, Questionnaire, Asthma, Diabetes
mellitus type 2, COPD, Shared decision making, Patient-centered care
Background
Over the last years, chronic conditions have emerged as
a major challenge to global health [1]. Concomitantly,
Patient Reported Outcome Measures (PROMs), such as
quality of life (QoL) and patients’ experienced burden of
disease, have gained prominence [2]. An agreed
definition for QoL and patients’ experienced burden of
disease is lacking. In this paper, burden of disease is de-
fined as a reflection of the impact of disease, which is
suffering due to symptom severity (intensity, frequency,
duration), functioning (occupational, social, and leisure
activities), and QoL (patients’ satisfaction with health,
occupational, social and leisure activities). This indicates
that QoL is an acknowledged and thus integrated part of
burden of disease [3]. The full scope of burden of disease
is rarely assessed in questionnaires. However, numerous
instruments have been developed to assess patients’ QoL
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[2]. These instruments might be used in clinical practice,
and are either generic or disease-specific. Generic instru-
ments have the ability to measure the overall QoL. This
is especially relevant for people with multimorbidity,
where approaches focussing on a single condition are
not convenient [4]. In contrast, disease-specific instru-
ments are more able to detect specific symptoms and
disease-related changes over time, at least for that spe-
cific condition [5]. Although several disease-specific in-
struments can be used in case of multimorbidity, it
might be inappropriate and difficult to attribute a spe-
cific complaint, such as fatigue, to one disease. Besides,
just completing one or more questionnaire(s) does not
in itself improve patient-centred care and shared deci-
sion making. To make a questionnaire more relevant in
daily healthcare, the outcomes should be integrated in
the conversation between the patient and the healthcare
provider, such as through visualisation of the results. A
need for an instrument that combines the benefits of
generic and disease-specific instruments is reinforced.
Additionally, this instrument should measure and visual-
ise the burden of one or more chronic conditions, and
give appropriate treatment advice. Therefore, the Assess-
ment of Burden of COPD (ABC)-tool will be reformed
into the Assessment of Burden of Chronic Conditions
(ABCC)-tool for multiple chronic conditions. The
current study focusses on COPD, asthma, and/or DM2,
because these are common diseases in general practice,
and due to funding possibilities.
The ABC-tool was developed in 2014 [6]. The tool
measures a patient’s integrated health status. In the
current paper, integrated health status is defined as the
experienced burden of disease and essential risk factors
for the chronic condition(s). The results are visualised
and integrated into the conversation between healthcare
provider and patient. This conversation is based on the
principles of shared decision making. The tool consists
of several components, namely the ABC-scale that mea-
sures the experienced burden of COPD, objective pa-
rameters and risk factors; a visualisation of the outcomes
based on cut-off points; and treatment advice [6]. Out-
comes of the ABC-scale are visualised using balloons,
such as displayed in Fig. 1 for the ABCC-tool. A balloon
represents a domain of the burden of disease or a risk
factor, and the colour and height indicate a patient’s
score on that domain. A red balloon indicates a low
score, an orange balloon indicates a moderate score, and
a green balloon indicates a high score. The height of the
balloons is based on cut-off points. Grey balloons visual-
ise domain scores of the previous visit, which enables to
monitor and visualise changes over time. If a patient and
healthcare provider select a balloon by clicking on it,
treatment advice is shown. Treatment advice include
among others self-management advice, suggestions for
different treatments, and possibilities for further discus-
sion. The advice is generic and based on current guide-
lines. An example of advice in the ABCC-tool is shown
in Fig. 2. Based on the discussion following the treat-
ment advice, personal care plans can be determined and
- where applicable - treatment advice can be operationa-
lised [6]. The ABC-tool has shown to be valid, reliable
and effective in improving QoL and perceived quality
of care [7, 8]. In general, patients and healthcare providers
respond positively to the tool [9]. Based on these positive
outcomes, the ABC-tool is currently being implemented
in daily primary care in the Netherlands.
The aim of the current study is to assess how the
ABC-tool can be transformed into the ABCC-tool for
patients with COPD, asthma and/or DM2 aged 18 years
and older. Secondary research questions are: 1) does an
appropriate questionnaire exist that assesses the burden
of asthma or DM2? and 2) which domains should be
included in a questionnaire to assess the burden of
COPD, asthma, and DM2 in adult patients?
Methods
The study includes a literature study and a qualitative
study, and consists of six consecutive phases. The study
was conducted in the Netherlands. In the first phase, re-
quirements were formulated that a questionnaire for the
burden of asthma and DM2 should meet. These require-
ments were based on the requirements that were estab-
lished during the development of the ABC-scale, and
were adapted if needed based on consensus in the re-
search group [6]. The research group consisted of four
researchers, including a professor in primary health care
(OS), an epidemiologist (EB), a health scientist (AG),
and a medical doctor (DC). Secondly, a literature study
was conducted to determine whether a questionnaire
existed that assesses the burden of asthma or DM2, and
that met the predefined requirements. This question-
naire could then serve as a basis for the development of
the ABCC-tool. The ABC-scale was based on the vali-
dated Clinical COPD Questionnaire [6]. The terms that
were included in the searches for asthma and DM2 are
displayed in Additional file 1.1. The searches were con-
ducted in October 2018 for DM2 and in November 2018
for asthma. One researcher (DC) assessed the titles and
abstracts of the studies regarding asthma, and one re-
searcher (EB) assessed the studies regarding DM2, to ex-
tract all existing questionnaires. Other questionnaires
were searched via the snowball method. Two researchers
(EB and DC) independently assessed whether the ques-
tionnaires met the requirements that were formulated in
phase 1. The outcomes were cross-checked between the
researchers and any disagreement was being resolved
through consensus. In the third phase, a first version of
the ABCC-scale was established based on the literature
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study, clinical experience, expert knowledge and the
Dutch College of General Practitioners’ guidelines.
Fourthly, interviews were conducted with patients and
healthcare providers. Patients were recruited through
general practices in the Netherlands. Healthcare pro-
viders were recruited via e-mail and included general
practitioners, internists, pulmonologists, and general
practice-based nurses. Interviews with healthcare pro-
viders were done face-to-face by one of the researchers
(EB or DC). From a constructivism point of view,
patients’ experienced burden and healthcare providers’
experiences concerning the experienced burden of pa-
tients were gathered. By means of phenomenology, these
lived experiences are combined into a synopsis that is
practical for daily healthcare practice. The aim of the in-
terviews with healthcare providers was to assess whether
the questionnaire and the associated domains were
appropriate and sufficient to determine the burden of
disease. During the interview, the preliminary ABCC-
scale was shown to the healthcare provider. The inter-
view guide consisted of the following topics: 1) do the
domains cover the burden of patients with COPD,
asthma and DM2?, 2) can the questions be used to iden-
tify if there is a problem in the domains of the ABCC-
scale?, and 3) are the questions logical and understand-
able? Patients were interviewed alone, in a duo-interview
or in a focus group by one or both of the researchers
(EB and/or DC). The aim of the interviews with patients
Fig. 2 Example of treatment advice (translated from the originally Dutch version)
Fig. 1 Visualisation of the integrated health status of a person with COPD and DM2
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was to determine the experienced burden of disease, and
to assess if the questions were logical and understand-
able. Patients were asked to write down their experi-
enced burden of disease. Subsequently, the topics that
were written down were discussed. If no other topics
emerged during the interviews, the preliminary ABCC-
scale was shown to the participating patients. Patients
were asked to complete the questionnaire, and indicate
if the questions were logical and understandable. Inter-
views were conducted until theoretical data saturation,
defined as the point at which no new themes emerged
from the interviews. The interviews were audio-recorded
and transcribed verbatim et literatim. The analyses were
performed manually. The transcripts were coded, and
emerging themes were identified by two researchers (EB
and DC). The themes were compared and interpreted by
these researchers. In case of any dispute a third re-
searcher (AS) was consulted in order to take a final deci-
sion. The study had an iterative character, i.e. the
questionnaire was adapted after several interviews, and
was then used in the next interviews. In the fifth phase,
the final content of the questionnaire was determined
during three meetings in collaboration with an expert
group, including among others general practitioners, dia-
betes mellitus specialists, and pulmonology specialists.
Two researchers (EB and DC) made an updated version
of the scale before each meeting based on the data from
the qualitative interviews and the expert group. During
the meeting, all attendees discussed which domains
should be included, which questions should address the
domains, and whether the questionnaire was compre-
hensible for patients. Consensus was reached based on
clinical expertise, expert knowledge, data from the inter-
views, and guidelines. Also the length of the question-
naire and balloon chart was taken into consideration.
Lastly, cut-off points and treatment advice were deter-
mined in an expert group consisting of the research
group, one pulmonologist (JV), one general practitioner
(PS), and one internist (HB) during two meetings. Two
researchers (EB and DC) made a first version of the cut-
off points and treatment advice before the meeting, and
all content was discussed during the meeting until con-
sensus was reached. Cut-off points and treatment advice
were based on the Dutch College of General Practi-
tioners’ guidelines, and formulated by the expert group.
These cut-off points determine the height and conse-
quently the colour of the balloon. Each balloon is
accompanied by different treatment advice, depending
on the cut-off points.
Results
In the first phase, several requirements for the ABCC-
scale were determined, based on the requirements for-
mulated for the ABC-scale [6]. Some requirements were
not apposite for the ABCC-tool, such as the possibility
to connect with generic QoL instruments, and were
therefore not taken into account. Requirements were
also added, such as the ability to measure burden of
medication use. It was concluded that the questionnaire
should: 1) include indicators that provide insight into
impairments, disabilities, complaints, and QoL due to
COPD, asthma or DM2, 2) measure symptoms, emo-
tions, limitations, social experiences, and burden of
medication use, 3) be based on patient input, 4) be easy
for both patients and caregivers to manage (takes less
than 10min to complete, includes subscores and a total
score, and potential to be self-administered by the pa-
tients), 5) be aimed to be used in daily healthcare prac-
tice, and 6) have good psychometric properties (validity,
reliability, responsiveness).
Secondly, the literature searches were conducted,
which resulted in 4820 and 3280 studies for DM2 and
asthma, respectively. Seventeen questionnaires were
identified for DM2 and 29 questionnaires were identified
for asthma. Additional files 1.2 and 1.3 show whether
the questionnaires met the requirements. In some cases,
it was doubtful if the questionnaire met the require-
ments, or no information was found in the literature. No
instruments were found that met all requirements.
Moreover, it was concluded that the use of validated
disease-specific questionnaires in the ABCC-scale is not
a favourable option, since these questionnaires are not
meant to be used in a scale for multiple chronic condi-
tions. In other words, the validated questionnaires would
have to be split up in generic and disease-specific ques-
tions, losing their validity as a result. Consequently,
questions from different questionnaires should be refor-
mulated to make consistencies in the generic question-
naire. Therefore, no existing questionnaires for DM2 or
asthma were used as a basis for the ABCC-scale.
During the third phase, a first version of the ABCC-
scale was developed. To construct a questionnaire that is
applicable both for patients with a single condition and
multiple conditions, the scale includes a generic ques-
tionnaire and disease-specific questionnaire(s). This fur-
thermore allows for the development of disease-specific
questionnaires for other common chronic conditions
within the same ABCC-tool. The disease-specific ques-
tionnaire(s) will be combined with the generic question-
naire, and they should not be used separately. The
patient will receive an individualised single scale, which
includes the generic questionnaire, and one or multiple
disease-specific questionnaire(s). The outcomes will be
visualised in one individualised balloon chart.
After the development of a first version of the ABCC-
scale, interviews were conducted with patients and
healthcare providers as part of phase four. Eighteen
healthcare providers were interviewed, including three
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general practice-based nurses, three general practi-
tioners, four pulmonologists, six internists, one diabetes
nurse, and one pulmonary nurse. Four healthcare pro-
viders were male, and fourteen healthcare providers
were female. Furthermore, twenty-one patients were
interviewed, including six patients with asthma, fourteen
patients with DM2, and two patients with COPD. One
patient was diagnosed with asthma and DM2. Ten pa-
tients were male, and eleven patients were female. The
themes that emerged during the interviews are broadly
reflected in the domains of the ABCC-tool. Some topics
emerged during interviews with healthcare providers but
not with patients, such as hypo-unawareness.
In the fifth phase, decisions on the final content of the
questionnaires were made based on feasibility, i.e. length
of the questionnaire and the balloon visualization, as
well as consensus in the expert group. Seven generic do-
mains that determine disease burden were identified, in-
cluding: 1) physical limitations, 2) fatigue, 3) night’s rest,
4) feelings/emotions, 5) sexuality, 6) relations and work,
and 7) medicines. To measure integrated health status,
other essential disease parameters and risk factors were
added, including 1) weight/body mass index, 2) physical
activity, 3) alcohol, and 4) smoking. For the DM2-scale,
four additional domains were identified, including: 1)
hypoglycaemia (described as hypo), 2) worry about blood
glucose, 3) leg- and feet complaints, and 4) eating and
drinking. The COPD-scale includes two additional do-
mains: 1) lung complaints, and 2) lung attacks (exacer-
bations). For the asthma-scale, three additional domains
were identified, including 1) asthma complaints, 2) nasal
complaints, and 3) lung attacks (exacerbations). Figure 1
displays an example of the balloon visualisation for
COPD and DM2. The number of questions per domain
range from one to four. Outcomes are scored using a 7-
point Likert scale. An open-ended question was added
to give a patient the option to address other topics or
questions. The scale consists of a total of 21, 23 and 24
questions, for DM2, COPD and asthma respectively.
Cut-off points and treatment advice were determined
by the expert group during the last phase. For example,
if a patient has an average score of three in the domain
feelings/emotions, a red balloon on a height of 30% will
be shown, with accompanying treatment advice. The
cut-off points are either based on an average score, or
are based on specific score combinations, based on
consensus in the expert group. An example of treatment
advice is shown in Fig. 2 and in Additional file 2.
Discussion
In this study, the ABC-tool was reformed into a disease-
specific ABCC-tool for COPD, asthma, and DM2. The
ABCC-scale fulfils the requirement to measure symptoms,
emotions, limitations, social experiences and burden of
medication use. The scale is based on input from patients,
health care providers, and experts, and is aimed at easy
administration.
PROMs are widely used to assess patient perspectives
on healthcare outcomes. In 2012, the International Con-
sortium for Health Outcomes Measurement (ICHOM)
was established to identify a standard set of outcomes
that reflects what matters most to patients [10]. Al-
though the potential role of ICHOM within the ABCC-
scale was studied, unfortunately no ICHOM set exists
for COPD or asthma to this day. Regarding DM2, the
ICHOM recommends to routinely assess psychological
well-being, diabetes distress and depression [11]. Al-
though these concepts are included in the ABCC-scale,
it was not desirable to include the associated question-
naires (the WHO-5, PAID and PHQ-9 respectively) be-
cause this would increase the length of the tool, and
therefore decrease the feasibility of the tool in daily prac-
tice. PROMs either measure general health or disease-
specific health, with in most PROMs emphasis on the
latter [12]. However, several studies have underlined the
relevance of combining the advantages of generic and
disease-specific questionnaires [2, 5, 13]. The ABCC-tool
may combine the conveniences of both, and as such -
and as far as we know - is unique in its kind. Complaints
that can originate from several chronic conditions do
not need to be attributable to one specific condition.
Moreover, patients only need to complete one question-
naire instead of one questionnaire for each condition,
and therefore user-friendliness is pursued.
Certainly in case of multimorbidity, care should be
person-centred instead of disease-centred, mainly fo-
cused on QoL, and promote self-management using
agreed personalised goals [4]. The ABCC-tool fits with
the vision that care for chronic conditions should not be
based on clinical outcomes alone, but also on physical,
mental and social well-being [13, 14]. Moreover, it is in
line with the thought of integrated care, viewing the pa-
tient in a holistic perspective and leading to advice that
is tailored to the patient’s needs [15]. Mounting evidence
indicates that patient-centered care could be the next
step in improving care for people with chronic condi-
tions [16–18]. Furthermore, the ABCC-tool is meant to
support self-management, because it helps formulating
personal care plans based on the discussion following
the treatment advice. The goals in the personal care plan
are chosen with the patient in the lead, which might in-
crease the motivation to work on the personal goals in
the home setting. This helps patients with a chronic
condition to live with the best possible QoL [19]. With
regard to diabetes, recommended care has shifted over
the past decade to an approach in which individualised
patient care and self-management support are essential
components [20]. Several studies highlight the
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importance of communication between patients and
healthcare providers in diabetes self-management [21–
23]. Health behaviour changes more likely occur if pa-
tients actively participate in setting their diabetes self-
care agenda [21]. Concerning asthma, self-management
education has been shown to reduce urgent healthcare,
work or school absences and sleep deprivation [24]. Re-
garding COPD, several domains such as severity, activity
and impact, should be taken into account in order to
properly capture the complexity and to provide the best
possible patient-centred care [25]. Multifactorial COPD
management might significantly improve health-related
QoL [26]. Several studies have shown that self-
management strategies improve a variety of health-
related outcomes for patients with COPD [27, 28].
A strength of the study is that it is based on the
principle and development of the ABC-tool, which has
shown to improve QoL and experienced quality of care
[8]. Besides, the development of the questionnaire was
based on a broad input, including a literature study,
guidelines from the Dutch College of General Practi-
tioners, and the input of healthcare providers, patients,
and researchers. Moreover, a strength of the tool is that
it not only quantifies, but also visualises the burden of
disease, provides domain-specific practical recommenda-
tions, and integrates burden of disease into a conversa-
tion based on shared decision making. This might aid
the translation of a score on a questionnaire to a tailor-
made care plan, and most likely increase the feasibility
of the tool in daily healthcare.
Although we have tried to include a diverse group of
patients, we cannot ensure to have an adequate repre-
sentation of the population with COPD, asthma and
DM2 (and any combination of these conditions) and
their healthcare providers. For example, only one patient
with multimorbidity was included in the qualitative
study. We aim to increase the number of patients with
multimorbidity during the next steps of this research.
Furthermore, we did not generate an item-bank and
perform item-reduction by means of statistical ana-
lysis. Instead, we determined the most important and
relevant items based on clinical expertise in expert
group meetings.
Further research is imperative to assess the validity
and reliability of the ABCC-scale, the (cost)-effective-
ness, and the feasibility of the tool. Moreover, research
should be conducted to understand the process of
implementing the tool in daily practice. It is recom-
mended to update treatment advice once important
changes in the guidelines have been made. The ABCC-
tool has currently been developed for COPD, asthma,
and DM2. The focus on these conditions was chosen
because these are common diseases in general practice,
and because of funding possibilities. Future aims are to
further develop the ABCC-tool for other common chronic
conditions, including mental diseases, cancer, and cardio-
vascular diseases such as heart failure and atrial fibrilla-
tion. In recent years, a plea for a new approach has been
made, in which treatable traits in airway diseases should
be identified and adequately treated [29, 30]. In future
research, it is aimed to assess whether the ABCC-tool can
play a role in tailored treatments, and whether the tool is
able to identify treatable traits.
Conclusions
This paper describes the development of the ABCC-
scale to assess the burden of COPD, asthma and/or
DM2, as well as the integrated ABCC-tool. The tool
consists of a questionnaire, a visualisation using balloons
that is based on cut-off points, and treatment advice.
The scale consists of a generic questionnaire, with items
that might be relevant for everyone with a chronic con-
dition, as well as disease-specific questionnaires. The
generic questionnaire will be combined with any amount
of disease-specific questionnaires (up to now: COPD,
asthma, and DM2) to form a single personalised scale
and balloon chart for each individual patient. The
ABCC-tool is intended to be used in daily healthcare
practice, is designed to monitor a patient’s integrated
health status over time, to facilitate shared decision mak-
ing, and to stimulate self-management.
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